Effentora er indiceret til behandling af gennembrudssmerter hos voksne med cancer, der i forvejen modtager opioid- vedligeholdelsesbehandling for kroniske cancersmerter.
Effentora is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain.